An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

Those with the sleep condition were more likely to develop Parkinson’s disease. But one treatment was found to help.

Novo Nordisk's older semaglutide version didn't meet expectations in trials to slow Alzheimer's cognitive decline. This ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB. N ...

In the Nat Geo documentary ‘A Roadtrip to Remember,’ actor Chris Hemsworth helps his dad use this therapy to combat Alzheimer ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

The following guide offers a detailed overview of several classes of medications that research links to a higher risk of ...

A study conducted by researchers at Saint Louis University found that people over 50 who suffer from both depression and ...